What is the market's earnings forecast for DocGo next quarter?

What were the key takeaways from DocGo's earnings call?

What were the key takeaways from DocGo’s earnings call?

Did DocGo beat or miss consensus estimates last quarter?

What is DocGo's gross profit margin?

What is the revenue and EPS growth rate for DocGo year over year?

What does DocGo do and what are its main business segments?

What factors drove the changes in DocGo's revenue and profit?

- **Revenue surge**: 2026 Mobile Health up 40%, SteadyMD $8M/Q4, Kentucky expansion. 
- **AI/automation**: 10-15% SG&A cuts via tech, 2026 EBITDA profitable. 
- **Strategic alternatives**: M&A and care gap programs, 2026 EBITDA positive Q4. 
- **Cash flow recovery**: migrant 97% Q2 collection, 2026 EBITDA loss $5-10M vs. prior $15-25M. 
- **Gross margin (32.5%→35%+), 2026 EBITDA profitable Q4, 2026 revenue 15-23%, 2026 EBITDA loss halved. 
- **Cross-selling**: care gap to primary care, mobile lab home visits, AI/automation 10-15% SG&A cuts. 
- **Strategic alternatives**: M&A, SteadyMD integration, and virtual care programs. 
- **Efficiency projects**: $5-6M annual savings, 2026 EBITDA profitable. 
- **Patient engagement**: AI/automation 92% NPS, 2026 EBITDA positive. 
- **Mobile Health**: remote monitoring 16% patient growth, 2026 EBITDA positive. 
- **Strategic alternatives**: M&A exploration, 2026 EBITDA profitable. 
- **AI/automation**: 10-15% SG&A cuts, 2026 EBITDA profitable Q4.

**【CEO Summary Section】**
- Q4 revenue $74.9M (YoY -30%), with SteadyMD contributing $8M Q4, up 50% in patient interactions. 
- 2026 revenue guidance to $290-310M, driven by care gap closures and virtual care ( Kentucky expansion), and AI/automation integration. 
- Cross-selling opportunities in mobile health (e.g., lab orders, virtual care, and EMS discharge support), NPS 92% satisfaction.
**【CFO Financial Commentary】
- 2026 EBITDA loss narrowed to $5-10M, with Mobile Health (remote monitoring, phlebotomy) and SteadyMD integration. 
- Efficiency projects to save $5-6M annually, reducing SG&A by 10-15%. 
- Cash flow challenges from migrant receivables, but 97% collection expected Q2. 
**【Q&A Highlights】
- Strategic alternatives exploration, including M&A, with SteadyMD and care gap programs, Kentucky launch. 
- Mobile Health cross-sell (e.g., lab orders to home visits), and AI/automation in billing, dispatch, and patient engagement. 
- 2026 EBITDA profitable by Q4, with transport hiring efficiency (overtime 13% → sub-10% target) and gross margin recovery (32.5% → 35%+), enabling 2026 profitability.

DocGo Inc. (DCGO) Q4 2025 Earnings Call Transcript

- **Strategic Acquisitions & Growth**: SteadyMD acquisition to drive virtual care expansion; 2026 revenue guidance $280-300M (+12-20% YoY). 
- **Transportation Scaling**: Hiring 700+ staff to capture $26K+ trips, targeting 12%+ margin. 
- **Financial Health**: Q3 2025 adjusted EBITDA loss $7.1M, cash $95.2M (debt-free). 
- **Payer-Provider Momentum**: Mobile Health 2025 $20.7M (non-migrant +20%), 2026 target $85M. 
- **Operational Efficiency**: 33% gross margin, $45M+ 2025 cash flow. 
- **Risk Management**: Migrant program winddown complete, 96% receivables collected. 
- **Market Position**: Leading in last-mile health care, 50-state virtual care footprint. 
- **Guidance Clarity**: 2026 EBITDA loss $15-25M, improving sequentially. 


**【CEO Summary Section】**
- **Record Volumes Across Core Businesses**: Q3 2025 saw record volumes in Medical Transportation and Mobile Health, excluding migrant-related services. 
- **SteadyMD Acquisition**: Acquired SteadyMD, a 50-state virtual care network with over 500 providers, for $25 million in 2025 revenue. 
- **2026 Guidance**: Revenue $280-300M (12-20% YoY growth), adjusted EBITDA loss $15-25M, with potential EBITDA positivity at top end. 
- **Transportation Growth**: $50.1M Q3 revenue, 12%+ margin target by 2026; plans to hire 700+ EMS staff to capture $26K+ outsourced trips annually. 
- **Payer-Provider Expansion**: 2025 Mobile Health revenue $20.7M (non-migrant +20% YoY), 2026 target $85M (SteadyMD contributes $25M). 
- **Remote Patient Monitoring**: $15M run rate, 10%+ EBITDA margin, 13 new contracts in 2025. 

**【CFO Financial Commentary】**
- **Q3 2025 Results**: Revenue $70.8M (8% YoY growth ex-migrant), adjusted EBITDA loss $7.1M. 
- **Gross Margins**: 33% (31.7% Transport, 36.2% Mobile Health). 
- **Cash Position**: $95.2M as of Q3, debt-free post-$30M credit line repayment. 
- **2026 Outlook**: $280-300M revenue, EBITDA loss $15-25M, improving sequentially. 

**【Q&A Highlights】**
- **Margins & SteadyMD Impact**: Q4 2025 EBITDA -13% (vs. Q3 -10%), SteadyMD adds $5M rev, EBITDA neutral. 
- **Payer-Provider Growth**: 2026 Mobile Health $85M (25% from SteadyMD), 2025 Care Gap Closure +400%. 
- **Transportation Scaling**: Hiring 700+ staff to capture $26K+ outsourced trips, targeting 12%+ margin. 
- **RPM Strategy**: Focused on cardiology, aligning with payer policy shifts. 
- **Cash Flow**: Q4 2025 cash ~$95M+, 2026 low point $65M. 
- **Migrant Winddown**: 2026 no migrant revenue, 2025 migrant $68-70M. 
- **Pipeline Expansion**: 2 top 10 payers expanding, 2 more in talks, 10 proposals. 
- **Market Sentiment**: Hospitals cautious on budgets, but outsourcing transport growing. 
- **Policy Impact**: Focused on cost-saving solutions, less reliant on government programs. 
- **Bookings**: Sequential growth in all segments, Q3 record volumes. 
- **End 2025 Cash**: ~$95M+, 2026 low point $65M. 


DocGo Inc. (DCGO) Q3 2025 Earnings Call Transcript

- **Revenue Decline**: Q2 2025 revenue ($80.4M) down 52% YoY due to migrant program wind-down. Mobile Health (-73% YoY), Transport (+3% YoY ex-CO). 
- **Operational Momentum**: 1.2M care gap patients (+33% QoQ), 176K transports, 6K gap visits, 28K phlebotomy visits. AI agent handled 3,350 appointments. 
- **Financial Health**: $128.7M cash (up $25.6M QoQ). Q2 2025 EBITDA loss ($6.1M) vs $17.2M profit YoY. 
- **Growth Drivers**: NY health system launch, VA deal, San Diego County contract. Target H2 2026 EBITDA positive. 
- **Margins**: 31.6% gross margin (down 230bps YoY). Transport margin 31.1% (up 200bps YoY). Mobile Health margin 32.5% (up 1.6pts QoQ). 
- **Cost Control**: SG&A down 7% YoY. $3.2M recurring costs (18% lower YoY). 
- **Share Buybacks**: $11M spent YTD, $11M remaining. 


**【CEO Summary Section】**
- **Revenue Growth**: Q2 2025 revenue was $80.4 million, down 52% YoY due to winding down migrant-related projects. Mobile Health revenue ($30.8M) declined 73% YoY, while Medical Transport ($49.6M) grew 3% YoY (excluding Colorado exit). 
- **Operational Metrics**: 176,000 medical transports, 6,000 care gap visits, and 28,000 mobile phlebotomy visits. Patient interactions hit 1.2 million in care gap closure program (+33% QoQ). 
- **AI Investment**: Text-based AI agent handled 3,350 appointments, saving 10% of operator time. Expanding to patient sign-ups. 
- **New Contracts**: Major NY health system launch (July 1), VA Medical Center deal, and San Diego County vaccination contract. 
- **Cash Flow**: $33.6M Q2 cash from ops, total cash $128.7M (up $25.6M QoQ). Repurchased 2.5M shares ($5.1M) under $11M buyback program. 

**【CFO Financial Commentary】**
- **Gross Margins**: 31.6% (Q2 2025) vs 33.9% (Q2 2024). Mobile Health margin 32.5% (up 1.6pts QoQ). Transport margin 31.1% (up 200bps YoY). 
- **Cost Control**: SG&A down 7% YoY ($3.2M recurring costs, 18% lower than Q2 2024). Field hiring (EMTs) for NY launch drove Q2 transport COGS. 
- **Guidance**: Target positive EBITDA by H2 2026 with $80-85M quarterly revenue, 33-35% gross margin, and 5-10% lower SG&A. 

**【Q&A Highlights】**
- **Patient Growth Without Revenue Impact**: +300K patients in care gap program (1.2M total) but revenue guidance unchanged due to field team ramp-up costs. 
- **Medical Transport Sequential Decline**: Q2 2025 ($49.6M) vs Q1 2025 ($50.2M). Seasonality and capacity utilization explained the 1% drop. 
- **EBITDA Margin Targets**: Transport business aiming for 10% EBITDA margin (currently 5-6%). Mobile Health margin expansion as payer/provider business scales. 
- **Colorado Exit Impact**: Q2 2024 had $1.8M in CO revenue, negligible in Q2 2025. Sequential decline due to Q1 overperformance in key markets. 
- **Share Repurchases**: $11M spent YTD on buyback program, $11M remaining. 


DocGo Inc. (DCGO) Q2 2025 Earnings Call Transcript

- **Government Vertical Removed**: $100M removed from 2025 guidance due to delays, revised to $300-330M revenue with $20-30M EBITDA loss.
- **Medical Transportation Growth**: 575,000 transports in 2025, 700,000 by 2026. Q1 revenue $50.8M (+5.4% YoY).
- **Payer Expansion**: Assigned lives 900,000, visits up 180% YoY. PCP visits to reach 40,000 in 2026. Mobile lab draws 125,000+ in 2025.
- **Cost Management**: Q1 SG&A down $3.1M, targeting positive cash flow ($9.7M Q1) despite EBITDA loss.
- **Tariffs Mitigated**: Fleet costs stable with new vehicle orders. Fuel costs lower than expected.

**【CEO Summary Section】**
- **Government Population Health Vertical Removed from Guidance**: Due to policy delays and budget cuts, DocGo removed $100 million in expected revenue from 2025 guidance, revising total revenue to $300-330 million with a $20-30 million EBITDA loss. Remaining core businesses (Medical Transportation, Payer & Provider, migrant services) remain on track at $225M, $50M, and $50M respectively.
- **Medical Transportation Growth**: Q1 2025 revenue $50.8M (+5.4% YoY), projecting 575,000 transports in 2025 and 700,000 by 2026. Northeast expansion and U.K. market growth key drivers. Gross margin 33.3%, improving sequentially.
- **Payer & Provider Expansion**: Assigned lives up 29% to 900,000. Visits grew from 2,500 (Q4 2023) to 4,400 (Q4 2024), projected 11,500 in Q4 2025. PCP visits expected to jump from 144 in 2024 to 10,000 in 2025 and 40,000 in 2026. Mobile lab services (PTI Health) to complete 125,000+ blood draws in 2025.
- **Cost Management**: Q1 SG&A down $3.1M sequentially, targeting further cuts. Positive cash flow ($9.7M Q1) expected for 2025 despite EBITDA loss, ending with $110M+ cash.

**【CFO Financial Commentary】**
- **Q1 2025 Results**: Total revenue $96M (-50% YoY), driven by migrant program wind-down. Mobile Health revenue $45.2M (-69% YoY), Medical Transportation $50.8M (+5.4% YoY). Adjusted EBITDA loss $3.9M vs. $24.1M YoY.
- **Gross Margins**: Total 28.2% (vs. 32.8% YoY). Mobile Health 30.8% (vs. 35.5% YoY) due to Payer & Provider scale-up. Medical Transportation 33.3% (stable vs. Q4 2024).
- **Balance Sheet**: $103.1M cash (down from $107.3M Q4 2024). $120M AR from migrant programs, expected to decline as payments continue. Stock buybacks ($9M YTD) and PTI acquisition ($4M) executed.

**【Q&A Highlights】**
- **Government Vertical Timing**: No material revenue expected in 2025, but upside if contracts launch. Q2 2025 low point for revenue, Q3 flattish, Q4 slight recovery.
- **Payer Demand**: MA plan expansion and quality metrics drive demand. Care gap closure visits quadrupling over 24 months. Net Promoter Score 86 vs. industry 58.
- **Tariffs Impact**: Fleet costs manageable with new vehicle orders placed. Fuel costs lower than projected, offsetting maintenance expenses.


DocGo (DCGO)-8 May 25-2025 Q1 Earnings call transcript

- **Revenue Resilience**: Maintained gross margin despite 39% YoY decline, driven by $70M+ base business growth. 
- **Strategic Investments**: $3.2M in care gap programs and PTI Health acquisition to accelerate 2025 expansion. 
- **Customer Expansion**: 120+ payer deals and 29 health system contracts in pipeline, with 1.5M+ patient interactions in 2024. 
- **Cash Flow Strength**: $107M cash balance (+49% YoY) and $70M operating cash flow, with $150M migrant AR to clear by mid-2025. 
- **Guidance 2025**: $410-450M revenue, mid-single-digit EBITDA margin, and 15%+ transport growth. 
- **Risk Mitigation**: Captive insurance saves $10M/year, offsetting self-insurance claims volatility. 


**【CEO Summary Section】**
- DocGo reported Q4 2024 revenue of $120.8 million, down 39% YoY due to migrant-related revenue decline, but maintained gross margin at 30.8%. 
- CEO Lee Bienstock highlighted aggressive investments in care gap closure programs, expanding into 31 U.S. states and the UK, with 1.5 million patient interactions in 2024. 
- Key customer expansions include major payers in New York and California adding mobile mammography, PCP services, and chronic care management. 
- Acquired PTI Health for mobile phlebotomy, and signed VA contracts for veteran care, driven by former VA Secretary Dr. David Shulkin. 
- Noted SG&A as a percentage of revenue rose to 39.7% in Q4 due to infrastructure investments, but expects sequential declines in 2025. 

**【CFO Financial Commentary】**
- Full year 2024 revenue was $616.6 million (-1% YoY), with adjusted EBITDA of $60.3 million (+12% YoY). 
- Mobile health revenue fell 4% YoY to $423.1 million, while medical transport grew 7% YoY to $113.5 million. 
- Q4 2024 adjusted EBITDA was $1.1 million vs $22.6 million YoY, missing guidance by $10 million due to migrant revenue shortfall and incremental investments. 
- Cash balance rose 49% YoY to $107.3 million, with $70.3 million in operating cash flow. 
- 2025 guidance: $410-450 million revenue, mid-single-digit EBITDA margin, and higher cash flow from shrinking AR ($210.9 million at year-end). 

**【Q&A Key Highlights】**
- **2025 Revenue Outlook**: Base business expected to offset $50 million migrant revenue, with 120+ payer deals and 29 health system contracts in pipeline. 
- **SG&A Management**: 2024 saw sequential SG&A declines (-7% Q1, -11% Q2, -13% Q3), but Q4 rose 20% due to strategic investments. 
- **Risk Mitigation**: Self-insurance claims added $3.2 million to Q4 EBITDA shortfall, but captive insurance saves ~$10M/year. 
- **Transport Growth**: 32% CAGR over 3 years, targeting 15%+ annual growth via new health system contracts. 
- **Migrant AR Collection**: $150 million migrant receivables expected to clear by mid-2025, driving cash flow tailwind. 
- **Care Gap Expansion**: Aiming for 65,000 care gap closures in 2025, up from 1,000 weekly visits in Q4 2024. 

**【Financial Metrics】**
- **Q4 2024**: 
  - Revenue: $120.8M (-39% YoY) 
  - Net Loss: $7.6M vs $8M profit YoY 
  - Adjusted EBITDA: $1.1M vs $22.6M YoY 
  - Gross Margin: 30.8% (flat YoY) 
  - DSO: 125 days (improved from 153 days YoY) 
- **Full Year 2024**: 
  - Revenue: $616.6M (-1% YoY) 
  - Adjusted EBITDA: $60.3M (+12% YoY) 
  - Cash Flow: $70.3M vs -$64.2M YoY 
  - AR: $210.9M (-20% YoY) 


Actual		0.09	0.11	0.03	0.11	-0.03	-0.02	0.05	0.075	0.1	0.06	0.05	-0.03	-0.09	-0.11	-0.28	-1.37
Forecast		0.0505	0.0365	0.0453	0.0707	0.0177	0.028	0.0617	0.0983	0.0767	0.0567	0.04	0.04	-0.0317	-0.1	-0.149	-0.142
Surprise	0.00%	+78.22%	+201.37%	-33.77%	+55.59%	-269.49%	-171.43%	-18.96%	-23.70%	+30.38%	+5.82%	+25.00%	-175.00%	-183.91%	-10.00%	-87.92%	-864.79%

DCGO

DCGO fundamentals

DCGO Q4 2025 Earnings

Earnings Call

You can ask Aime

DCGO

DCGO fundamentals

DCGO Q4 2025 Earnings

Earnings Call

DCGO Earnings Call Summary for Q4/20255:00 PM on Mar 16, 2026

DCGO Earnings Call Summary for Q3/20255:00 PM on Nov 10, 2025

DCGO Earnings Call Summary for Q2/20255:00 PM on Aug 7, 2025

DCGO Earnings Call Summary for Q1/20255:00 PM on May 8, 2025

DCGO Earnings Call Summary for Q4/20245:00 PM on Feb 27, 2025

You can ask Aime